

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE
01 AUG 17 AM

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Katcher Vaughn & Bailey Communications			
2. Address <input checked="" type="checkbox"/> Check if different than previously reported 5141 Virginia Way, Suite 420			
3. Principal Place of Business (if different from line 2) City: Brentwood State/Zip (or Country) TN 37027			
4. Contact Name Greg Bailey	Telephone (615) 248-8202	E-mail (optional)	5. Senate ID # 62415-12
7. Client Name <input type="checkbox"/> Self Pharmaceutical Research & Manufacturers of America (PhRMA)			6. House ID # 354570

TYPE OF REPORT 8. Year 2001 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇒ Termination Date _____ 11. No Lobbying Activities

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> ⇒ <u>\$20,000</u> Income (nearest \$20,000)	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input checked="" type="checkbox"/> \$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of: <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition <input type="checkbox"/> Method B. Reporting amounts under section 6033(e) Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code

Signature _____

Printed Name and Title _____



Registrant Name Katcher Vaughn & Bailey Client Name Pharmaceutical Research & Mar

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

1. Discussed PhRMA's opposition to the reimportation of prescription drugs as a safety hazard to consumers. No specific legislation Addressed.
2. Discussed PhRMA's opposition to any regulation of pharmaceutical prices. HR 1400, The Prescription Drug Fairness Act, as it pertained to the regulation of prices was referenced.

17. House(s) of Congress and Federal agencies contacted

Check if None

U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Matt Haney	
Greg Bailey	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature _____ Date _____

Printed Name and Title _____



Registrant Name Katcher Vaughn & Bailey Client Name PhRMA

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the regi engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, pr information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

Discussed PhRMA's support for Medicare reform and the addition of a prescription drug benefit. Outlined PhRMA's preferences for reform based on free market approaches. Referenced generally as models S.3! Medicare Preservation and Improvement Act of 2001, and S.358, Medicare Prescription Drug and Modernization Act of 2001.

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Matt Haney	
Greg Bailey	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date _____

Printed Name and Title _____



Registrant Name Katcher Vaughn & Bailey Client Name PhRMA

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the regi engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, pr information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

Communicated broadly the pharmaceutical industry's concern about research and development of new drugs. Particularly the effects government mandated price controls would have on the industry's abi to conduct new research.


17. House(s) of Congress and Federal agencies contacted Check if None

U.S. House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Matt Haney	
Greg Bailey	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/14/01

Printed Name and Title Greg Bailey, Partner

U -

